Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Kian Behbakht and Benjamin Bitler.

 
Connection Strength
 
 
 
2.951
 
  1. Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol. 2017 12; 147(3):695-704.
    View in: PubMed
    Score: 0.637
  2. Greenwood A, Woodruff ER, Nguyen C, Piper C, Clauset A, Brubaker LW, Behbakht K, Bitler BG. Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors: A Systematic Review. Obstet Gynecol. 2024 Mar 01; 143(3):e63-e77.
    View in: PubMed
    Score: 0.245
  3. Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BG. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. bioRxiv. 2023 Feb 23.
    View in: PubMed
    Score: 0.231
  4. McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Mol Cancer Res. 2023 01 03; 21(1):3-13.
    View in: PubMed
    Score: 0.229
  5. Yamamoto TM, Webb PG, Davis DM, Baumgartner HK, Woodruff ER, Guntupalli SR, Neville M, Behbakht K, Bitler BG. Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Mol Cancer Ther. 2022 04 01; 21(4):647-657.
    View in: PubMed
    Score: 0.217
  6. Clauset A, Behbakht K, Bitler BG. Decoding the dynamic tumor microenvironment. Sci Adv. 2021 06; 7(23).
    View in: PubMed
    Score: 0.205
  7. Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 12 01; 26(23):6362-6373.
    View in: PubMed
    Score: 0.195
  8. Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 07; 18(7):1088-1098.
    View in: PubMed
    Score: 0.188
  9. Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.
    View in: PubMed
    Score: 0.184
  10. Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. Mol Cancer Ther. 2020 02; 19(2):602-613.
    View in: PubMed
    Score: 0.182
  11. Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 10; 58(10):1770-1782.
    View in: PubMed
    Score: 0.179
  12. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018 Nov 26; 7(11):92.
    View in: PubMed
    Score: 0.172
  13. Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019 Nov; 461(1-2):37-46.
    View in: PubMed
    Score: 0.045
  14. Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 03; 17(3):741-750.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)